ICLR vs SYRE
ICON Public Limited Company vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
ICLR
ICON Public Limited Company
68
Buy
VS
SYRE
Spyre Therapeutics, Inc.
70
Buy
| Metric | ICLR | SYRE |
|---|
| AI Score |
68
|
70
|
| Price |
$163.01
|
$103.56
|
| P/E Ratio |
39.04×
|
-52.23×
|
| ROE |
2.5%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
21.8%
|
0.0%
|
| Debt / Equity |
0.37×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.0
|
49.5
|
| Beta |
1.203
|
3.026
|
| Expected Upside |
+17.5%
|
—
|
AI Committee View
Current Innellis committee reasoning for ICLR versus SYRE.
SYRE leads by 2 points.
SYRE scores 70/100 (Buy) versus ICLR at 68/100 (Buy).
ICLR Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical